A17 |
رقم الكتالوجGC91591
One-Click Copy Product Info
|
A17 is a bile acid derivative.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2568186-47-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
A17 is a bile acid derivative.[1] It reduces triglyceride accumulation induced by oleic acid , increases cell viability, and decreases oleic acid-induced lipid peroxidation in primary rat hepatocytes when used at concentrations of 10 and 25 µM. A17 (25 µM) reduces levels of CD36, also known as scavenger receptor B2 or fatty acid translocase, in primary rat hepatocytes. In vivo, A17 (50 mg/kg) reduces serum triglyceride, total cholesterol, and LDL levels, reverses hepatic steatosis, and decreases hepatic triglyceride, but not total cholesterol, levels in a hamster model of high-fat diet-induced non-alcoholic steatohepatitis (NASH).
References:
[1].Wang, Y., Zhu, Y., Niu, J., et al.A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamstersToxicol. Appl. Pharmacol.404115169(2020).
| Cas No. | 2568186-47-8 | SDF | |
| Formula | C31H51NO6 | M.Wt | 533.7 |
| الذوبان | Chloroform: Sparingly soluble: 1-10 mg/ml,Methanol: Slightly soluble: 0.1-1 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8737 mL | 9.3686 mL | 18.7371 mL |
| 5 mM | 374.7 μL | 1.8737 mL | 3.7474 mL |
| 10 mM | 187.4 μL | 936.9 μL | 1.8737 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)